Market Update on Amgen Inc. (NASDAQ:AMGN) – Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets

October 22, 2013 at 09:03 AM EDT

[PR Newswire] - THOUSAND OAKS, Calif., Oct. 22, 2013 - Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with F. Hoffmann-La Roche (“Roche”) to acquire Roche’s rights to filgrastim and pegfilgrastim in . . . → Read More: Market Update on Amgen Inc. (NASDAQ:AMGN) – Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets Similar posts: Surface RT recovery image released to fix Windows RT 8.1 update issues – Microsoft Corporation (NYSE:MSFT) [at The Verge] – Microsoft is releasing a Surface... Company Update: Oracle Corporation (NYSE:ORCL) – Oracle acquires Compendium [theflyonthewall.com] – Oracle announced that it has acquired Compendium,... Company Update: Qualcomm Incorporated (NASDAQ:QCOM) – Qualcomm Incorporated (NASDAQ: QCOM) Fourth Quarter and Fiscal 2013 Earnings Release and Conference Call [PR Newswire] – SAN DIEGO, Oct. 16, 2013 /PRNewswire-FirstCall/...

Amgen Inc. (NASDAQ:AMGN) [PR Newswire] - THOUSAND OAKS, Calif., Oct. 22, 2013 - Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with F. Hoffmann-La Roche (“Roche”) to acquire Roche’s rights to filgrastim and pegfilgrastim in approximately 100 markets, effective Jan. 1, 2014.

Roche has held the rights to filgrastim and pegfilgrastim under license from Kirin-Amgen, Inc. (a joint venture between Amgen and Kirin Holdings Co. Limited, of Japan) in Eastern Europe, Latin America, … [visit site to read more]